Brixton Biosciences key facts
- Developer of a biomedical neuromodulation therapy designed to sustain pain relief and support mobility.
- It has raised $41.0M; the latest was Grant ($1.0M) in Oct 2024.
- Notable investors include National Institutes of Health, SV Health Investors, FemHealth Ventures, Schooner Capital, Sparta Group — 11 tracked in total.
- Status: Privately Held (backing).
Who backs Brixton Biosciences
11+- ·The complete investor list: 11 names
- ·Watch Brixton Biosciences: the Monday email on marks, rounds and moves
Brixton Biosciences funding rounds
No funding rounds for Brixton Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Brixton Biosciences investors
11 investors are on record for Brixton Biosciences, including National Institutes of Health, SV Health Investors, FemHealth Ventures and Schooner Capital. By type, the record holds 2 venture capital firms, 2 family offices and 1 growth equity firm.
About Brixton Biosciences
Developer of a biomedical neuromodulation therapy designed to sustain pain relief and support mobility. The company offers a proprietary neural cooling implant technology, featuring minimally invasive delivery, long-duration effects, and academic validation, enabling patients with chronic or acute musculoskeletal pain to regain function and reduce discomfort.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2019
- Website
- brixtonbio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Brixton Biosciences doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.